[Place of clinical pharmacist in the management of drugs in patients with hypertension]. / Place du pharmacien clinicien dans la prise en charge thérapeutique du patient hypertendu.

PURPOSE: To synthesize pharmacists' interventions made in the department of internal medicine and hypertension of university hospital of Toulouse and assess the impact on medication orders. METHODS: This is a single-center, prospective study using pharmacists' interventions recorded between September 2013 and March 2014 on the Act-IP(©) website of the French Society of Clinical Pharmacy. The clinical pharmacist is present everyday in the unit to establish the medication reconciliation of new patients (the process of comparing a patient's medication orders to all of the medications that the patient has been taking), and analysis of medication orders. When a risk of iatrogenic drug is identified, a therapeutic change is proposed to the prescriber. RESULTS: A total of 2491 medication orders were analyzed for 7 months, leading to 39 pharmacists' interventions (1.6 pharmacists' interventions per 100 medication orders). The most commonly identified drug-related problems were improper administration (33%, n=13), not prescribed drug (21%, n=8), non-conformity to guidelines (18%, n=7), supratherapeutic dose (15%, n=6), and 13% (n=5) targeted prescribed treatment not administered, underdosing, incorrect administration or drug interaction. The most relevant molecules were atorvastatin (10%), bromazepam (8%) and levothyroxine (8%) and only 2 interventions targeted antihypertensive drugs. The rate of physicians' acceptance was 92%. CONCLUSION: Pharmacists' interventions mainly concern the co-prescriptions of antihypertensive drugs and very few antihypertensive drugs. The clinical pharmacist contributes to preventing iatrogenic in patients with hypertension with a very good acceptance by the clinician.

[Hyperreactive malarial splenomegaly: three clinical cases and literature review]. / Splénomégalie palustre hyperimmune : à propos de trois cas cliniques et revue de la littérature.

Hyperreactive malarial splenomegaly (HMS) is the chronic stage of a long-term stimulation of the immune system secondary to plasmodial infections, more frequently in genetically predisposed patients. HMS is a leading cause of large tropical splenomegaly in endemic zones but has been described in immigrants from Africa and in some European expatriates living in endemic countries. Diagnostic criteria include: long-term stay in a endemic zone, often large splenomegaly, high IgM titer, high antiplasmodial antibody titer, regression by at least 40% of splenomegaly six months after curative antimalarial treatment. In tropical settings, B-cell lymphoma and splenic lymphoma are the main differential diagnoses, which may be identified by a clonality analysis. Recent studies suggest that HMS can be treated by a short-term antimalarial therapy as long as the patient resides out of a malarial endemic country.

[Dyslipidemia in uremic patients at the National Hospital of Donka-Conakry]. / Profil lipidique des urémiques a l'Hôptal National de Donka à Conakry.

The prevalence of the dyslipidemia is higher at the patients in chronic renal failure (CRF) than in the general population. The objective of this study was to determine the prevalence and the lipidic anomalies among uraemic patients and to evaluate the others associated factors of cardiovascular risk. The study was descriptive with prospective recruitment (November 2004-June 2005); concerned 60 patients having an advanced chronic renal failure whose calculated clearance of creatinin was lower than 30 ml/mn as well as the hemodialysed patients. The lipidic disturbances on the whole 9/16 dialysed (56%) and 31 uraermia /44 were not dialysed (70%). This majority triglyceride dyslipidemia comprised 8 cases of hypertriglyceridemia in the group of dialysed patients against 19 in the group of not dialysed; 1 case of mixed hyperlipidemia against 6 cases and 4 cases of hypercholesterolemia HDL in the non dialysed group with 1 case of HDL low cholesterol. The patients with dyslipidemia were 4 females (25%) and 5 males (31%) among dialysed group; and of 13 female (29%) and 18 male (41%) among not dialysed. The average age was of 54.3 +/- 0.7 years for dialysed against the 46.6 +/- 0.2 years for the dyslipidémia in the non dialysed. Among others factors of cardiovascular risk, the arterial high blood pressure was noted at 9 dialysed patient's dyslipidémia and 20 case / 31 to the not dialysed dyslipidémia; and the diabetes was observed in 1 and 3 cases respectively. The addiction to smoking was noted in both groups except at the dialysis patients not dyalipidémiques.